Howard L. Kaplan

2.6k total citations
63 papers, 2.0k citations indexed

About

Howard L. Kaplan is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Howard L. Kaplan has authored 63 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cellular and Molecular Neuroscience, 11 papers in Psychiatry and Mental health and 8 papers in Pharmacology. Recurrent topics in Howard L. Kaplan's work include Neurotransmitter Receptor Influence on Behavior (10 papers), Opioid Use Disorder Treatment (8 papers) and Alcoholism and Thiamine Deficiency (6 papers). Howard L. Kaplan is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (10 papers), Opioid Use Disorder Treatment (8 papers) and Alcoholism and Thiamine Deficiency (6 papers). Howard L. Kaplan collaborates with scholars based in Canada, United States and Sweden. Howard L. Kaplan's co-authors include Neil A. Macmillan, Edward M. Sellers, C. Douglas Creelman, Usoa E. Busto, Gail Somer, Joanne Shaw, Paul Sandor, Laurie Zawertailo, Myroslava K. Romach and U. Busto and has published in prestigious journals such as Science, Psychological Bulletin and American Journal of Psychiatry.

In The Last Decade

Howard L. Kaplan

62 papers receiving 1.9k citations

Peers

Countries citing papers authored by Howard L. Kaplan

Since Specialization

Citations

This map shows the geographic impact of Howard L. Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard L. Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard L. Kaplan more than expected).

Fields of papers citing papers by Howard L. Kaplan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard L. Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard L. Kaplan. The network helps show where Howard L. Kaplan may publish in the future.

Co-authorship network of co-authors of Howard L. Kaplan

This figure shows the co-authorship network connecting the top 25 collaborators of Howard L. Kaplan. A scholar is included among the top collaborators of Howard L. Kaplan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard L. Kaplan. Howard L. Kaplan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital 2003 ·Journal of Clinical Psychopharmacology ·Laurie Zawertailo, Usoa E. Busto, Howard L. Kaplan, David J. Greenblatt, Edward M. Sellers	21
2	The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo 2003 ·Journal of Clinical Psychopharmacology ·(unknown), U. Busto, Rachel F. Tyndale, Howard L. Kaplan, Edward M. Sellers	12
3	Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability 2000 ·Journal of Clinical Psychopharmacology ·(unknown), Howard L. Kaplan, Myroslava K. Romach, Usoa E. Busto, Ningyuan Li, Juliette Säwe, Rachel F. Tyndale, Edward M. Sellers	40
4	A Comparative Pharmacokinetic and Dynamic Evaluation of Alprazolam Sustained-Release, Bromazepam, and Lorazepam 2000 ·Journal of Clinical Psychopharmacology ·Usoa E. Busto, Howard L. Kaplan, Caroline Wright, Baltazar Gomez‐Mancilla, Laurie Zawertailo, David J. Greenblatt, Edward M. Sellers	16
5	Comparative Abuse Liability of Intravenously Administered Remifentanil and Fentanyl 2000 ·Journal of Clinical Psychopharmacology ·(unknown), Howard L. Kaplan, Gail Somer, Usoa E. Busto, Edward M. Sellers	28
6	Attenuation of the Euphoric Effects of Cocaine by the Dopamine D1/D5 Antagonist Ecopipam (SCH 39166) 1999 ·Archives of General Psychiatry ·Myroslava K. Romach, Paul Glue, Kyle M. Kampman, Howard L. Kaplan, Gail Somer, (unknown), Laura Clarke, Vicki L. Coffin, James Cornish, Charles P. O’Brien, Edward M. Sellers	89
7	Building Your Own Web Course: The Case for Off-the-Shelf Component Software. 1998 ·Howard L. Kaplan	8
8	A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation 1998 ·Journal of Clinical Psychopharmacology ·Myroslava K. Romach, Howard L. Kaplan, Usoa E. Busto, Gail Somer, Edward M. Sellers	33
9	Inhibition of Cytochrome P450 2D6 Metabolism of Hydrocodone to Hydromorphone Does Not Importantly Affect Abuse Liability 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Howard L. Kaplan, Usoa E. Busto, (unknown), Siu Wah Cheung, S. Victoria Otton, Gail Somer, Edward M. Sellers	40
10	Comparative Abuse Liability of Sertraline, Alprazolam, and Dextroamphetamine in Humans 1995 ·Journal of Clinical Psychopharmacology ·Laurie Zawertailo, Usoa Busto, Howard L. Kaplan, Edward M. Sellers	33
11	Clinical aspects of chronic use of alprazolam and lorazepam 1995 ·American Journal of Psychiatry ·Myroslava K. Romach, U. Busto, Gail Somer, Howard L. Kaplan, Edward M. Sellers	39
12	Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans 1994 ·Clinical Pharmacology & Therapeutics ·Usoa Busto, Howard L. Kaplan, Laurie Zawertailo, Edward M. Sellers	43
13	CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone 1993 ·Clinical Pharmacology & Therapeutics ·S V Otton, (unknown), Siu Wah Cheung, Howard L. Kaplan, Usoa E. Busto, Edward M. Sellers	144
14	Characteristics of Long-term Alprazolam Users in the Community 1992 ·Journal of Clinical Psychopharmacology ·(unknown), Gail Somer, Linda C. Sobell, Mark B. Sobell, Howard L. Kaplan, Edward M. Sellers	21
15	Representation of on-line questionnaires in an editable, auditable database 1992 ·Behavior Research Methods, Instruments, & Computers ·Howard L. Kaplan	7
16	Kinetic and dynamic interactions of oral viqualine and ethanol in man 1989 ·European Journal of Clinical Pharmacology ·John T. Sullivan, C. A. Naranjo, (unknown), Howard L. Kaplan, K Kadlec, Edward M. Sellers	9
17	A general framework for defining evoked potential paradigms 1989 ·Behavior Research Methods, Instruments, & Computers ·Howard L. Kaplan, (unknown)	2
18	Development of Optimal Treatment Tactics for Alcohol Withdrawal. I. Assessment and Effectiveness of Supportive Care 1981 ·Journal of Clinical Psychopharmacology ·Joanne Shaw, (unknown), Edward M. Sellers, Howard L. Kaplan, Paul Sandor	186
19	Age- and sex-related differences in patterns of drug overdose and abuse 1981 ·PubMed ·Usoa Busto, Howard L. Kaplan, Edward M. Sellers	5
20	A shared-memory approach to microprocessor program development 1979 ·Behavior Research Methods ·Howard L. Kaplan, Dominique M. Durand	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact